comparemela.com

Latest Breaking News On - Global blood therapeutic - Page 1 : comparemela.com

Editas Medicine Stock: Assessing Impact Of Casgevy And Lyfgenia Approvals (NASDAQ:EDIT)

Editas Medicine Stock: Assessing Impact Of Casgevy And Lyfgenia Approvals (NASDAQ:EDIT)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Pfizer (PFE) Quarterly Report 2023

Pfizer on Tuesday reported first-quarter sales and adjusted earnings that beat Wall Street expectations, despite a decline in sales attributed to lower demand

Pfizer Completes Acquisition of Global Blood Therapeutics

Pfizer Completes Acquisition of Global Blood Therapeutics
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Pfizer Completes Acquisition of Global Blood Therapeutics

Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient communityNEW YORK (BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutica.

Global Blood Therapeutics, Inc (NASDAQ:GBT) Expected to Earn FY2022 Earnings of ($4 55) Per Share

Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for Global Blood Therapeutics in a research report issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.55) per share for the year. Cantor Fitzgerald currently has a “Neutral” […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.